Third U.S. patent on Teva's MS drug invalidated

U.S. patent officials have invalidated a third patent covering Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment glatiramer acetate (Copaxone), after cancelling two other patents on the drug recently. The ruling came in a challenge at the U.S.

U.S. patent officials have invalidated a third patent covering Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment glatiramer acetate (Copaxone), after cancelling two other patents on the drug recently. The ruling came in a challenge at the U.S. Patent and Trademark Office by Mylan, which is trying to bring out a generic version of the 40-milligram injectable drug. According to FDA, Teva's drug is protected by five patents in total.